Pertussis (Whooping Cough) – Drugs in Development, 2021
- Pages: 143
- Published: November 2021
- Report Code: GMDHC13184IDB
Global Markets Direct’s, ‘Pertussis (Whooping Cough) – Drugs in Development, 2021’, provides an overview of the Pertussis (Whooping Cough) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough)
– The report reviews pipeline therapeutics for Pertussis (Whooping Cough) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Pertussis (Whooping Cough) therapeutics and enlists all their major and minor projects
– The report assesses Pertussis (Whooping Cough) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pertussis (Whooping Cough)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Adjuvance Technologies Inc
AIM Vaccine Co Ltd
Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Bharat Biotech Ltd
Biken Co Ltd
Biological E Ltd
BioNet-Asia Co Ltd
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
DBV Technologies SA
Dynavax Technologies Corp
Faron Pharmaceuticals Oy
Gamaleya Federal Research Center of Epidemiology and Microbiology
GC Pharma
GlaxoSmithKline Plc
ILiAD Biotechnologies LLC
KM Biologics Co Ltd
LG Chem Ltd
Novo Medi Sciences Pvt Ltd
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi
Serum Institute of India Pvt Ltd
Shantha Biotechnics Pvt Ltd
Suzhou Weichao Biotechnology Co Ltd
Synthetic Biologics Inc
VaxForm LLC
Yisheng Biopharma Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.